title: High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.
abstract: Neisseria meningitidis of serogroup B (MenB) is currently responsible for more than 70% of cases of invasive meningococcal disease (IMD) in Poland and Europe as a whole. The aim of this study was to estimate strain coverage of a multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland; the meningococcal antigen typing system (MATS) was used to test a panel of 196 invasive MenB strains isolated in Poland in 2010 and 2011. The strains were also characterized by MLST and sequencing of porA, factor H-binding protein (fHbp), Neisserial heparin-binding antigen (nhba) and Neisserial adhesin A (nadA) genes. MATS and molecular data were analyzed independently and in combination. The MATS results predicted that 83.7% (95% CI: 78.6-91.0%) of isolates would be covered by the 4CMenB vaccine; 59.2% by one vaccine antigen, 19.9% by two and 4.6% by three antigens. Coverage by each antigen was as follows: fHbp 73.0% (95% CI: 68.9-77.5%), NHBA 28.6% (95% CI: 13.3-47.4%), NadA 1.0% (95% CI: 1.0-2.0%) and PorA 10.2%. Molecular analysis revealed that the most frequent clonal complexes (ccs) were cc32 (33.2%), cc18 (17.9%) and cc41/44 (15.8%) with estimated coverage of 98.5%, 88.6% and 93.5%, respectively. Consistent with findings for other European countries, our study predicts high coverage by the 4CMenB vaccine in Poland.
authors.affiliation: National Reference Centre for Bacterial Meningitis (NRCBM), National Medicines Institute, Warsaw, Poland.
authors.forename: Izabela
authors.initials: I
authors.lastname: Waśko
authors.affiliation: Institute Pasteur, Invasive Bacterial Infections Unit, Paris, France.
authors.forename: Eva
authors.initials: E
authors.lastname: Hong
authors.affiliation: Novartis Vaccines and Diagnostics, Siena, Italy.
authors.forename: Rosita
authors.initials: R
authors.lastname: De Paola
authors.affiliation: Novartis Vaccines and Diagnostics, Siena, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Stella
authors.affiliation: Novartis Vaccines and Diagnostics, Siena, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Moschioni
authors.affiliation: Institute Pasteur, Invasive Bacterial Infections Unit, Paris, France.
authors.forename: Muhamed-Kheir
authors.initials: MK
authors.lastname: Taha
authors.affiliation: National Reference Centre for Bacterial Meningitis (NRCBM), National Medicines Institute, Warsaw, Poland. Electronic address: skoczek@cls.edu.pl.
authors.forename: Anna
authors.initials: A
authors.lastname: Skoczyńska
mesh_terms: D018829:Adhesins, Bacterial / Q000235:genetics; D000293:Adolescent; D000328:Adult; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology; D001426:Bacterial Proteins / Q000235:genetics; D015373:Bacterial Typing Techniques; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008589:Meningococcal Infections / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology*; D058885:Multilocus Sequence Typing; D038541:Neisseria meningitidis, Serogroup B / Q000145:classification*; D011044:Poland; D018272:Porins / Q000235:genetics; D065288:Serogroup; D055815:Young Adult
chemical_list: C570015:4CMenB vaccine; D018829:Adhesins, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D022401:Meningococcal Vaccines; C501982:NadA protein, Neisseria meningitidis; D018272:Porins; C484699:factor H-binding protein, Neisseria meningitidis; C057699:porin protein, Neisseria
keywords: 4CMenB vaccine; MATS; Meningococcal disease; Vaccine coverage